White matter microstructure in relatives of people with schizophrenia or bipolar disorder: an ENIGMA meta-analysis.

Mol PsychiatryMay 21, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Marjolein E A Barendse, Simon R Poortman, Christopher R K Ching et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined white matter microstructure in unaffected first-degree relatives of individuals with bipolar disorder (FDR-BD) and schizophrenia (FDR-SZ) compared to controls. The study included 408 FDR-BD, 542 FDR-SZ, and 841 controls. FDR-BD exhibited higher mean fractional anisotropy (FA) in the posterior limb of the internal capsule than controls, while FDR-SZ showed no significant FA differences.

Key findings

  • FDR-BD had higher FA in the posterior limb of the internal capsule than controls.
  • FDR-SZ did not show any FA differences from controls.
  • Participants with BD or SZ had lower FA than controls in several tracts.
  • Working memory scores were positively related to FA in the PLIC in FDR-SZ.

Why it matters

Understanding white matter microstructure in relatives of individuals with bipolar disorder and schizophrenia can help clarify the neurobiological underpinnings of these disorders and their heritability, potentially guiding future research and interventions.

Source

Published in Mol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.